Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.54 |
| ▸ | MEN1 | O00255 | 5/20 | 0.54 |
| ▸ | USP2 | O75604 | 5/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 4/20 | 0.54 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | ATM | Q13315 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | CHAT | P28329 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20735091 | 0.82 | KMT2A (0.63) | KMT2AMEN1USP2KEAP1NFE2L2 | |
| SCHEMBL21609610 | 0.81 | CHAT (0.46) | KMT2AMEN1USP2KEAP1NFE2L2 | |
| SCHEMBL25988462 | 0.80 | GRM5 (0.37) | KMT2AMEN1USP2KEAP1NFE2L2 | |
| SCHEMBL25066288 | 0.79 | POLB (0.38) | KMT2AMEN1USP2KEAP1NFE2L2 | |
| SCHEMBL13901466 | 0.79 | KMT2A (0.59) | KMT2AMEN1USP2KEAP1NFE2L2 | |
| SCHEMBL20735127 | 0.78 | KMT2A (0.71) | KMT2AMEN1USP2KEAP1NFE2L2 | |
| SCHEMBL12869500 | 0.76 | KMT2A (0.73) | KMT2AMEN1USP2KEAP1NFE2L2 | |
| SCHEMBL20735058 | 0.73 | KMT2A (0.65) | KMT2AMEN1USP2KEAP1NFE2L2 | |
| SCHEMBL20735019 | 0.72 | KMT2A (0.63) | KMT2AMEN1USP2KEAP1NFE2L2 | |
| SCHEMBL26556567 | 0.72 | MEN1 (0.53) | KMT2AMEN1USP2KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037319-B2 | Curable compound | DAICEL CORPORATION (JP) | 2024-07-16 | — | — | US | disclosed |
| US-12037319-B2 | Curable compound | DAICEL CORPORATION (JP) | 2024-07-16 | — | — | US | disclosed |
| US-20240067777-A1 | CURABLE COMPOUND PRODUCT | DAICEL CORPORATION (JP) | 2024-02-29 | — | — | US | disclosed |
| US-20240067777-A1 | CURABLE COMPOUND PRODUCT | DAICEL CORPORATION (JP) | 2024-02-29 | — | — | US | disclosed |
| US-20240026076-A1 | CURABLE COMPOUND PRODUCT | DAICEL CORPORATION (JP) | 2024-01-25 | — | — | US | disclosed |
| US-20240026076-A1 | CURABLE COMPOUND PRODUCT | DAICEL CORPORATION (JP) | 2024-01-25 | — | — | US | disclosed |
| US-20230373916-A1 | CURABLE COMPOUND PRODUCT | DAICEL CORPORATION (JP) | 2023-11-23 | — | — | US | disclosed |
| US-20230373916-A1 | CURABLE COMPOUND PRODUCT | DAICEL CORPORATION (JP) | 2023-11-23 | — | — | US | disclosed |
| WO-2022133984-A1 | CURABLE COMPOUND PRODUCT | DAICEL CORPORATION (JP) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022075324-A1 | CURABLE COMPOUND PRODUCT | 株式会社ダイセル | 2022-04-14 | — | — | WO | disclosed |
| US-20210253527-A1 | CURABLE COMPOUND | DAICEL CORPORATION (JP) | 2021-08-19 | — | — | US | disclosed |
| WO-2021124681-A1 | CURABLE COMPOSITION | 株式会社ダイセル | 2021-06-24 | — | — | WO | disclosed |
| US-11021438-B2 | Curable compound | DAICEL CORPORATION (JP) | 2021-06-01 | — | — | US | disclosed |
| WO-2019244694-A1 | CURABLE COMPOUND | 株式会社ダイセル | 2019-12-26 | — | — | WO | disclosed |
| WO-2019244693-A1 | CURABLE COMPOSITION | 株式会社ダイセル | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037319-B2 | Curable compound | CCT5, PGA5, KDM5B | KMT2A 1311/4885MEN1 2220/4885USP2 1348/4885 |
| US-20210253527-A1 | CURABLE COMPOUND | CCT5, PGA5, KDM5B | KMT2A 1311/4885MEN1 2220/4885USP2 1348/4885 |
| US-20230373916-A1 | CURABLE COMPOUND PRODUCT | RPLP0, SSRP1, RPP30 | KMT2A 1893/4885MEN1 788/4885USP2 244/4885 |
| US-11021438-B2 | Curable compound | CNOT1, CCNH, ASH2L | KMT2A 2200/4885MEN1 723/4885USP2 1141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.